Swedish study of 4033 incident RA vs 6485 controls - Exposure to occupational inhalable increased risk ACPA+ RA (OR 1.25). Occupational inhalable agents plus smoking and shared epitope markedly elevated risk (OR 18.22) esp in ACPA+RA https://t.co/4lKLEhkURm https://t.co/HFhz8lMR10

Study of 172 febrile pts w skin rash + arthralgia; 112 Dx w/ #AOSD. Use of a "streamlined diagnostic process (looking @ neutrophilia, hyperferritinemia, high IL-18), shortened Dx time (2 vs 4 wks), earlier Dx and more remissions (85% vs 68%, p < 0.05) https://t.co/MSMq2XLeYA https://t.co/ECKkeVqTIW

Biosimilar Bonanza in 2023 Dr. Jack Cush reviews more than a dozen news and journal articles from this past week on RheumNow https://t.co/FILyCcSThn https://t.co/kBxzZgs6rM

2022 ACR/EULAR Giant Cell Arteritis Classification Criteria Giant cell arteritis (GCA) has historically been a clinical diagnosis (visual loss, headache, jaw pain, scalp tenderness, etc) supported by labs and histopathology. https://t.co/inHKcdXLmD https://t.co/g9v1zWkmRp

Small, open label study of 43 RA pts Rx w/ csDMARDs randomized to denosumab or PBO x 24 weeks. Erosions of MCP 2,3 assessed by HR-pQCT shows no significant differences in erosions or safety signals at 6 mos between groups. https://t.co/AuysVPFD4S https://t.co/yQ4R41hSMi

FROST study (First-line options sJIA Tx) - a prospective study to assess treatments in SJIA. 86% Rx w/ biologic (IL-1/IL-6 i) & 14% non-biologic Rx. oral GC used in 54% biologic & 90% of non-biologic. 1/2 non-biologic went onto biologics w/in 4 mos. https://t.co/8TMpEPgzOr https://t.co/N8laSs5rrZ

The Best Prescription The craziest question that you can ask any doctor is “what is your best therapy for __?”. Crazy, because there are exponential answers, with factored layers that make each decision unique to that doctor. https://t.co/iX8T6NSD00 https://t.co/8VUPbDjXzr

73-87% of autoimmune (RA, SLE, UCTD, APL) pts used HCQ during pregnancy. HCQ significantly reduced pre-eclampsia (20% vs 9%), early-onset pre-eclampsia (8% vs 2.5%), 2nd/3rd trimester pregnancy loss (3% vs. 0.6%) https://t.co/KrA3XtGNmK https://t.co/HwpmipgJYC

From a cohort of 689 SLE pts, prevalence of lupus pericarditis was 16.4% Pericarditis was signif assoc w/ renal dz (p 0.003), lymphopenia (p <.0001), thrombocytopenia (p 0.004), +APL Abs (p = 0.002) https://t.co/BndDu21aXF https://t.co/Umbq3rsF1y

207 JIA pts to rheumatology studied. Initially 61% seen by Pediatrics but only 28% referred to rheumatologist. Mean time to Dx was 56 days, but longer for polyarticular & ERA/SPA (~114 d). Faster dx w/ Younger age & fever; longer w/ sm jts https://t.co/5D8wiGxnC2 https://t.co/1n9S4JUdfF

Retrospective study in RA shows Red cell distribution width (RDW) & absolute lymphocyte count (ALC) predict 10 yr mortality (P < 0.001); highest with both high RDW and low ALC. Data developed on 327 VA RA pts & validated on national cohort (13,914) https://t.co/aBGECUfKGH https://t.co/qkvv1PmvSB

Review of the Rheumatic causes of Pericarditis and their management. Causes: SLE, RA, MCTD, Myositis, EGPA, GPA, IgG4-rel Dz, FMF, TRAPS, CAPS, AOSD, JIA, Sarcoidosis, Kawasakis, GCA, Takayasu's https://t.co/h6zpTOIuyu https://t.co/Gy3Eaqz8sM